-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Understanding Differential Technologies for Detection of MRD and How to Incorporate into Clinical Practice

Program: Education Program
Session: What are Treatment Options for Patients with Relapsed, Refractory or Persistent AML?
Hematology Disease Topics & Pathways:
Research, Acute Myeloid Malignancies, AML, adult, Translational Research, CHIP, assays, hematopoiesis, Diseases, Myeloid Malignancies, Biological Processes, Technology and Procedures, Study Population, Human, Minimal Residual Disease , molecular testing
Saturday, December 9, 2023, 9:30 AM-10:45 AM

Jacqueline Cloos, MD

Cancer Center Amsterdam, Department of Hematology, Amsterdam UMC, Location VUMC, Amsterdam, Netherlands

Disclosures: Cloos: BD Biosciences: Patents & Royalties: Royalties LSC tube; Navigate: Consultancy, Patents & Royalties: Royalties MRD assay; Novartis: Consultancy, Research Funding; Takeda: Research Funding; Astellas: Speakers Bureau.

See more of: What are Treatment Options for Patients with Relapsed, Refractory or Persistent AML?
See more of: Education Program
Previous Presentation | Next Presentation >>